ECSP044959A

ECSP044959A - VIVIC POLYMERASE INHIBITORS

Info

Publication number: ECSP044959A
Authority: EC
Inventors: Pierre Louis Beaulieu; Eric Jolicoeur; Marc Andre Poupart; Youla S Tsantrizos; Sylvie Goulet; Jean Rancourt; Martin Poirier; Gulrez Fazal; George Kukolj; James Gillard
Original assignee: Boehringer Ingelheim Canada Ltd
Priority date: 2001-12-07
Filing date: 2004-01-23
Publication date: 2004-03-23

Abstract

Un isómero, enantiómero, diastereoisómero o tautómero de un compuestos, representado por la fórmula I: donde A es O, S, NR1 o CR1, donde R1 está definido aquí; representando un enlace simple o un enlace doble; R2 es seleccionado de: H. halógeno, R21, O R21, SR21, COOR21, SO2N(R22)2, N(R22)2, CON(R22)2, NR22C(O)R22 o NR22C(O)NR22 donde R21 y cada R22 es definido aquí; B es NR3 o CR3, con la cláusula de que uno de A o B es CR1 o CR3, donde R3 está definido aquí; K es N o CR4, donde R4 está definido aquí; L es N o CR5, donde R5 tiene la misma definición como R4; M es N o CR7, donde R7 tiene la misma definición como R4; Y1 es O o S; Z es N(R6a)R6 o OR6, donde R6a es H o alquil o NR61R62 donde R61 y R62 están definidos aquí; y R6 es H. alquil, cicloalquil, alquenil, Het, alquil-aril, alquil-Het; o R6 es donde R7 y R8 y Q están definidos aquí; Y2 es O o S; R9 es H, (C1-6) alquil, (C3-7)cicloalquil o (C1-6) alquil-(C3-7) cicloalquil, aril, Het, (C1-6)alquil-aril o (C1-6) alquil-Het, todo de lo cual opcionalmente sustituido con R90; o R9 es unido covalentemente a R7 o R8 para formar un heterociclo 5- o 6 miembros; una sal o un derivado del mismo, como un inhibidor de HCV NS5B polimerasa.An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: where A is O, S, NR1 or CR1, where R1 is defined herein; representing a single bond or a double bond; R2 is selected from: H. halogen, R21, O R21, SR21, COOR21, SO2N (R22) 2, N (R22) 2, CON (R22) 2, NR22C (O) R22 or NR22C (O) NR22 where R21 and each R22 is defined here; B is NR3 or CR3, with the clause that one of A or B is CR1 or CR3, where R3 is defined here; K is N or CR4, where R4 is defined here; L is N or CR5, where R5 has the same definition as R4; M is N or CR7, where R7 has the same definition as R4; Y1 is O or S; Z is N (R6a) R6 or OR6, where R6a is H or alkyl or NR61R62 where R61 and R62 are defined herein; and R6 is H. alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R6 is where R7 and R8 and Q are defined here; Y2 is O or S; R9 is H, (C1-6) alkyl, (C3-7) cycloalkyl or (C1-6) alkyl- (C3-7) cycloalkyl, aryl, Het, (C1-6) alkyl-aryl or (C1-6) alkyl-Het, all of which optionally substituted with R90; or R9 is covalently linked to R7 or R8 to form a 5- or 6-membered heterocycle; a salt or a derivative thereof, such as an NSVB polymerase HCV inhibitor.